Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Gastric Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Uterine Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Head and Neck Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Liver Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Cervical Cancer

Clinical Trial at: Texas Oncology - Dallas

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

  • Details

ClinicalTrials.gov ID: NCT03894215
Diagnosis Type: NA
USOR Number: 18223

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Dallas

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

  • Details

ClinicalTrials.gov ID: NCT03056755
Diagnosis Type: NA
USOR Number: 17026

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

  • Details

ClinicalTrials.gov ID: NCT03262935
Diagnosis Type: NA
USOR Number: 17027

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Pages